RxDoctor Payments Data

Anthony Inguaggiato, MD

Cardiovascular Disease · Union City, NJNPI 1336219948

Payments from drug & device makers

$818in general payments, 2019–2025

Across 49 payments — averaging $16.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$321
  • E.r. Squibb & Sons, L.L.C.$149
  • Johnson & Johnson$94
  • Merck$73
  • Tactile Systems Technology Inc$36
  • Boston Scientific$35
  • plus $110 from 5 others

What the payments were for

  • Food & beverage$818100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boehringer Ingelheim22$321
E.r. Squibb & Sons, L.L.C.3$149
Johnson & Johnson8$94
Merck5$73
Tactile Systems Technology Inc1$36
Boston Scientific2$35
G Medical Diagnostic Services, Inc.3$32
Pfizer2$29
Bayer1$22
AbbVie1$15
Bardy Diagnostics, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$818 in reported general payments places this provider in the 20th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$182,030
Medicare patients
153
Services billed
1,984

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban230$139,212
XareltoRivaroxaban36$27,124
JanuviaSitagliptin Phosphate20$26,295
LinzessLinaclotide23$21,643
JardianceEmpagliflozin38$17,246
Breo ElliptaFluticasone/Vilanterol37$16,473
TradjentaLinagliptin23$12,759
Dexlansoprazole DrDexlansoprazole22$9,970
VascepaIcosapent Ethyl17$7,452
BrilintaTicagrelor13$7,016
Advair HfaFluticasone Propion/Salmeterol18$6,601
Metoprolol Succinate169$3,624
Nebivolol Hcl63$3,182
Losartan Potassium214$2,965
Rosuvastatin Calcium153$2,691

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$29$139,212230 claims
Boehringer IngelheimJardiance, Tradjenta$321$30,00661 claims
Johnson & JohnsonXarelto$94$27,12436 claims
MerckJanuvia$73$26,29520 claims
AbbVieLinzess$15$21,64323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Union City

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →